Aza-bridged-bicyclic amino acid derivatives as α4...

Details Aza-bridged-bicyclic amino acid derivatives as α4... Aza-bridged-bicyclic amino acid derivatives as α4...

2005-11-01

2005-11-01

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S112000, C548S452000, C548S465000, C544S127000, C544S362000, C514S235200, C514S253030, C514S412000, C514S414000

Reexamination Certificate

active

06960597

ABSTRACT:
The invention is directed to aza-bridged-bicyclic compounds having Formula (I):and pharmaceutically acceptable salts thereof. The compounds are useful (α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

REFERENCES:
patent: 3905971 (1975-09-01), Miller
patent: 5034391 (1991-07-01), Blaschke et al.
patent: 5523308 (1996-06-01), Costanzo et al.
patent: 5525623 (1996-06-01), Spear et al.
patent: 5827860 (1998-10-01), Costanzo et al.
patent: 5827866 (1998-10-01), Costanzo et al.
patent: 6090785 (2000-07-01), Durette et al.
patent: 6191171 (2001-02-01), DeLaszlo et al.
patent: 6221888 (2001-04-01), Durette et al.
patent: 6229011 (2001-05-01), Chen et al.
patent: 6291511 (2001-09-01), Durette et al.
patent: 6353099 (2002-03-01), DeLaszlo et al.
patent: 6380387 (2002-04-01), Sidduri et al.
patent: 6388084 (2002-05-01), Kaplan et al.
patent: 6403584 (2002-06-01), de Laszlo et al.
patent: 6407066 (2002-06-01), Dressen et al.
patent: 6420418 (2002-07-01), Hagmann et al.
patent: 6426348 (2002-07-01), Hull et al.
patent: 6455550 (2002-09-01), Chen et al.
patent: 6469036 (2002-10-01), Costanzo et al.
patent: 6479519 (2002-11-01), Astles et al.
patent: 6479666 (2002-11-01), Hull et al.
patent: 6521666 (2003-02-01), Sircar et al.
patent: 6534513 (2003-03-01), Porter et al.
patent: 6559174 (2003-05-01), Lin et al.
patent: 6579889 (2003-06-01), de Laszlo et al.
patent: 2002/0019402 (2002-02-01), Dominguez et al.
patent: 2002/0085882 (2002-07-01), Konradi et al.
patent: 2002/0091115 (2002-07-01), Dyatkin et al.
patent: 2002/0133015 (2002-09-01), Kaplan et al.
patent: 2002/0137935 (2002-09-01), Head et al.
patent: 2002/0197233 (2002-12-01), Relton et al.
patent: 2003/0018195 (2003-01-01), Konradi et al.
patent: 2003/0027771 (2003-02-01), Dressen et al.
patent: 2003/0027850 (2003-02-01), Ashwell et al.
patent: 2003/0100585 (2003-05-01), Duplantier et al.
patent: 2003/0130166 (2003-07-01), Cunningham
patent: 0252422 (1999-07-01), None
patent: 0947506 (1999-10-01), None
patent: WO 99/06433 (1990-02-01), None
patent: WO 98/53814 (1998-12-01), None
patent: 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06435 (1999-02-01), None
patent: WO 99/06436 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/23063 (1999-05-01), None
patent: WO 99/35163 (1999-07-01), None
patent: WO 99/36393 (1999-07-01), None
patent: WO 99/43642 (1999-09-01), None
patent: WO 99/48879 (1999-09-01), None
patent: WO 99/61465 (1999-12-01), None
patent: WO 99/643900 (1999-12-01), None
patent: WO 00/01690 (2000-01-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 00/20396 (2000-04-01), None
patent: WO 00/43354 (2000-07-01), None
patent: WO 01/14328 (2001-03-01), None
patent: WO 01/21584 (2001-03-01), None
patent: WO 01/32610 (2001-05-01), None
patent: WO 01/42215 (2001-06-01), None
patent: WO 01/42225 (2001-06-01), None
patent: WO 01/54690 (2001-08-01), None
patent: WO 02/08202 (2002-01-01), None
patent: WO 02/057242 (2002-07-01), None
patent: WO 01/36376 (2002-08-01), None
patent: WO 03/010135 (2003-02-01), None
patent: WO 02/16329 (2003-03-01), None
patent: WO 01/28830 (2003-07-01), None
patent: WO 02/22563 (2003-07-01), None
PCT Search Report for PCT/US 01/20857 dated Mar. 18, 2002.
Osborn, L.; et al., Cell, 1989, 59, 1203.
Wayner, E. A.; et al., Cell Biol., 1989, 109, 1321.
Bayless, K. J.; et al., J. Cell Sci., 1998, 111, 1165.
Adams, S. P.; et al., Ann. Rep. Med. Chem., 1999, 34, 179.
Chuluyan, H. E.; et al., Springer Semin. Immunopathol., 1995, 16, 391.
Simmons, P. J.; et al., Blood, 1992, 80, 388.
Shroff, H. N.; et al., Bioorg. Med. Chem. Lett., 1998, 8, 1601.
Yoshikawa, H.; et al., J. Immunol., 1996, 156, 1832.
Laberge, S.; et al., Am. J. Respir. Crit. Care Med., 1995, 151, 822.
Barbadillo, C.; et al., Springer Semin. Immunopathol., 1995, 16, 375.
Powrie, F.; et al., Ther. Immunol., 1995, 2, 115.
Tamraz, S.; et al., Springer Semin. Immunopathol. 1995, 16, 437.
Molossi, S.; et al., J. Clin. Invest. 1995, 95, 2601.
Lin, K-C.; et al., J. Med. Chem. 1999, 42, 920.
Kling D, Fingerle J, Harlan JM, Lobb, RR and Lang, F, Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD-18 and VLA-4-dependent mechanisms and stimulate smooth muscle migration, Circ. Res., 1995, 77, 1121-1128.
Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson S and Harker L, Anti-VLA-4 antibody reduces intimal hyperplasis in the endarterectomized carotid artery in non-human primates, J. Vasc. Surg., 1997, 26, 87-93.
Labinez M, Hoeffert C, pels K, Aggarawal S, Pepinsky RB, Leonw D, Koteliansky V, Lobb, RR and O'Brien EO, Infustion on and anti-alpha4 integrin antibody is associated with less adventitial formation after balloon injury of porcine coronary arteries, Can. J. Cardiol., 2000, 16, 187-196.
O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, et al., Vascular cell adhesion molecule-1 is expressed in human atherosclerotic plaques: implications for the mode of progression of advanced atherosclerosis, J. Clin. Invest., 1993, 92, 945-951.
Nakahima Y, Raines EW, Plump AS, Breslow JL and Ross R, Upregulation of VCAM-1 and ICAM-1 at atherosclerotic-prone sites on the endothelium of ApoE-deficient mouse, Arterioscler. Thromb. Vasc. Biol., 1998, 18, 842-851.
Ilyama K, Hajra L, Iiyam M, Li,H, DiChura M, Medoff BD and Cybulsky MI, Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesion and at sites predisposed to lesion formation, Circ. Res., 1999, 85, 199-207.
Shih PT, Brennan M-L, Vora DK, Territo MC, Strahl D, Elices MJ, Aldons J and Berliner JA, Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet, Circ. Res., 1999, 84, 345-351.
Huo Y, Hafez-Moghadem A and Ley K, Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions, Circ. Res., 2000, 87, 153-159.
Hamann, A.; et al., J. Immunol. 1994, 152, 3282.
Hanninen, A.C.; et al., J. Clin. Invest. 1993, 92, 2509.
Fong, S.; et al., Immunol. Res. 1997, 16, 299.
Yang, X.; et al., Diabetes 1997, 46, 1542.
Gould, Philip L., Ref. International J. Pharm., 1986, 33, 201-217.
Berge et al., J. Pharm.Sci., (Jan., 1997), 66, 1, 1.
W. Abraham et al., “Formamidinoyl Isothiocyanales—III. Addition of Nucleophilic Partners to Formamidinoyl Isothiocyanates,” Tetrahedron 29, 669-705 (1973).

Affiliated with

Also associated with

Rating

Aza-bridged-bicyclic amino acid derivatives as α4... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aza-bridged-bicyclic amino acid derivatives as α4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza-bridged-bicyclic amino acid derivatives as α4... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3460334